Navigation Links
Jubilant and Endo Pharmaceuticals Announce Successful Delivery of Early Milestones in Collaborative Discovery Program
Date:2/9/2012

BANGALORE, India, February 9, 2012 /PRNewswire/ --

Jubilant Biosys Ltd., a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd., announced today that they have achieved an early stage milestone in one of their collaborative programs with Chadds Ford, Pa., USA-based Endo Pharmaceuticals that has nominated a candidate into full development. The novel molecule, targeting cancer, is anticipated to go into clinical trials by late 2012. Jubilant and Endo will continue the collaboration in the development phase as well.  

The multi-target collaboration that began three years ago focuses on Best in Class differentiated therapies to address the unmet needs of cancer patients worldwide.  The collaboration has since delivered multiple milestones across the discovery phase.  Endo will pursue development and commercialization of the compound, while Jubilant becomes eligible to receive development milestones.

"We are very pleased and elated with this successful outcome, which is a result of the excellent collaboration between the scientists at Endo and Jubilant," said Sri Mosur, CEO & President, Global Drug Discovery and Development, Jubilant. "Jubilant has pioneered from India, a business model based on shared risk that enables it to demonstrate the differentiated and novel outcomes that Jubilant scientists are able to deliver through accelerated and affordable innovation to its many collaborators."

Sandeep Gupta, Endo Pharmaceuticals, Senior Vice President, Discovery & Early Development , said, "I congratulate the Jubilant and Endo teams on achieving this important milestone. It was their outstanding collaborative work and ingenuity that enabled nomination of a development candidate ahead of schedule in less than two years since inception of this program. Initiation of this development program further validates Endo's unique collabrative drug discovery approach which aims to address unmet medical needs and improve patient outcomes."  

About Us

Jubilant Biosys Ltd. is a Bengaluru based subsidiary of Jubilant Life Sciences Ltd, headquartered in Noida, India. Jubilant Biosys, provides integrated drug discovery and development solutions to the global pharmaceutical industry. It is a pioneer in collaborative discovery research and development and is engaged in multiple partnerships with global pharmaceutical industry in therapeutic areas of Oncology, CNS and CVMED.

http://www.jubilantbiosys.com

Contact For Business Queries

Narendra Kumar
+91(0)80-6662840
narendra_kumar@jubilantbiosys.com


'/>"/>
SOURCE Jubilant Biosys Ltd and Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jubilant HollisterStier Allergy Launches Allergy Industry Insights Educational Webinar Series
2. Jubilant and AstraZeneca Announce Successful Delivery of Early Milestones in Drug Discovery
3. Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture
4. Jubilant Enters Research Collaboration With AstraZeneca
5. Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models
6. Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain
7. Prismic Pharmaceuticals Acquires Scaristas Exclusive License to Amarins Omega-3 Patents for CNS Disorders
8. Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
9. Cadence Pharmaceuticals Announces Voluntary Recall of One Lot of OFIRMEV® (Acetaminophen) Injection
10. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
11. Generic Pharmaceuticals Market - A Global Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... June 14, 2017  ivWatch LLC, a medical device ... intravenous (IV) therapy, is pleased to announce it was ... Nonsurgical Hospital Supplies and Equipment at the 2017 Medical ... the medtech industry. The award was presented by Medical ... Javits Center in New York ...
(Date:6/11/2017)...  Eli Lilly and Company (NYSE: LLY ) ... of galcanezumab, an investigational treatment for the prevention of ... key secondary endpoints for galcanezumab compared to placebo at ... EVOLVE-2 and REGAIN) will be presented today at the ... Boston . "The detailed ...
(Date:6/8/2017)...   Responding to Heath Ledger,s father,s recent ... singer Chris Cornell in May, the mental health ... free online psychiatric drug side effects search ... psychotropic drug risks. The father of the ... accidental overdose, has called for tighter rules on prescription drugs. ...
Breaking Medicine Technology:
(Date:6/24/2017)... ... ... The weather is heating up and the days are getting longer, providing the ... the summer months provide more than warmer temperatures that are perfect for BBQ’s and ... from direct exposure to the sun. When it comes to the security of homes ...
(Date:6/23/2017)... ... June 23, 2017 , ... The ... launch of Care Management Alerts and Dashboards, an innovative new service enabling healthcare ... , RIQI’s Care Management Alerts and Dashboards provide near real-time data about patients ...
(Date:6/23/2017)... CA (PRWEB) , ... June 23, 2017 , ... By ... earned its ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ... the top 1% of all charities reviewed by Charity Navigator and earns ANRF a ...
(Date:6/23/2017)... ... ... show evidence that carotenoids and antioxidants derived either from the diet or from supplements ... often do ophthalmologists and optometrists in Sweden recommend the use of nutritional supplements, changes ... of AMD? A study published recently in Dove Medical Press journal, ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... surgeon practicing in Newburgh, New York, has recently begun offering three new minimally ... offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited to ...
Breaking Medicine News(10 mins):